EU Green Light In Sight For Aimovig; 12 Drugs In Line For Potential CHMP Decision
The European Medicines Agency's drug evaluation committee, the CHMP, will this week decide whether up to a dozen products that have been through the evaluation process should be recommended for approval in throughout the EU.
You may also be interested in...
Enasidenib, which last year became the first US-approved treatment for relapsed or refractory acute myeloid leukemia with an IDH2 mutation, is among a new crop of products being reviewed for marketing approval in the EU.
Six orphan drugs – including the first two CAR-T cell therapies in the EU – may get the green light from the European Medicines Agency at its June meeting this week. Will the negative opinion handed down earlier this year on Puma Biotechnology’s Nerlynx be overturned, though?